STOCK TITAN

[144] Abivax S.A. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

ABVX: A stockholder filed a Form 144 to sell up to 1,200,000 ADS, with an aggregate market value of $111,300,000. The proposed sale is listed for approximately 10/28/2025 through Leerink Partners on the NASDAQ.

The securities were acquired in the IPO on 10/20/2023, with 1,200,000 ADS purchased from the issuer and paid in cash on 10/24/2023. Shares outstanding were 77,800,000; this is a baseline figure, not the amount being offered.

ABVX: un azionista ha presentato un modulo 144 per vendere fino a 1.200.000 ADS, con un valore di mercato aggregato di 111.300.000 dollari. La vendita proposta è indicata per circa il 28/10/2025 tramite Leerink Partners sul NASDAQ.

Le securities sono state acquisite nell'offerta pubblica iniziale il 20/10/2023, con 1.200.000 ADS acquistate dall'emittente e pagate in contanti il 24/10/2023. Le azioni in circolazione erano 77.800.000; questa è una cifra di base, non l'ammontare offerto.

ABVX: un accionista presentó un Formulario 144 para vender hasta 1.200.000 ADS, con un valor de mercado agregado de 111.300.000 dólares. La venta propuesta figura aproximadamente para el 28/10/2025 a través de Leerink Partners en NASDAQ.

Los valores se adquirieron en la OPV el 20/10/2023, con 1.200.000 ADS compradas al emisor y pagadas en efectivo el 24/10/2023. Las acciones en circulación eran 77.800.000; esta es una cifra base, no la cantidad que se ofrece.

ABVX: 주주가 Form 144를 제출하여 최대 1,200,000 ADS를 매도하고, 총 시가가 1억1130만 달러인 내용. 제안된 매도는 NASDAQ의 Leerink Partners를 통해 약 2025년 10월 28일에 시작될 예정입니다.

이 증권은 2023년 10월 20일 IPO에서 취득되었으며, 발행사로부터 1,200,000 ADS를 현금으로 2023년 10월 24일에 매입했습니다. 발행 주식 수는 77,800,000주였으며, 이는 기초 수치로써 제공되는 수량이 아닙니다.

ABVX : un actionnaire a déposé un Form 144 pour vendre jusqu'à 1 200 000 ADS, pour une valeur de marché cumulée de 111 300 000 dollars. La vente proposée est inscrite pour environ le 28/10/2025 via Leerink Partners sur le NASDAQ.

Les valeurs mobilières ont été acquises lors de l'introduction en bourse le 20/10/2023, avec 1 200 000 ADS achetées auprès de l'émetteur et payées en espèces le 24/10/2023. Les actions en circulation étaient de 77 800 000 ; il s'agit d'un chiffre de base, non le montant offert.

ABVX: Ein Aktionär hat ein Formular 144 eingereicht, um bis zu 1.200.000 ADS zu verkaufen, mit einem aggregierten Marktwert von 111.300.000 USD. Der vorgeschlagene Verkauf ist voraussichtlich ab dem ca. 28.10.2025 über Leerink Partners an der NASDAQ gelistet.

Die Wertpapiere wurden im IPO am 20.10.2023 erworben, wobei 1.200.000 ADS vom Emittenten gekauft und am 24.10.2023 in bar bezahlt wurden. Die ausstehenden Aktien betrugen 77.800.000; dies ist eine Basiszahl, nicht der angebotene Betrag.

ABVX: قدّم مساهم استمارة 144 لبيع حتى 1,200,000 ADS، بقيمة سوقية إجمالية قدرها 111,300,000 دولار. البيع المقترح مُدرج حوالي 28/10/2025 عبر Leerink Partners في NASDAQ.

تم الحصول على الأوراق المالية في اكتتاب عام أولي في 20/10/2023، مع شراء 1,200,000 ADS من المصدر ودفعها نقداً في 24/10/2023. كانت الأسهم المتداولة 77,800,000؛ هذه قيمة أساسية، وليست المبلغ المعروض.

Positive
  • None.
Negative
  • None.

ABVX: un azionista ha presentato un modulo 144 per vendere fino a 1.200.000 ADS, con un valore di mercato aggregato di 111.300.000 dollari. La vendita proposta è indicata per circa il 28/10/2025 tramite Leerink Partners sul NASDAQ.

Le securities sono state acquisite nell'offerta pubblica iniziale il 20/10/2023, con 1.200.000 ADS acquistate dall'emittente e pagate in contanti il 24/10/2023. Le azioni in circolazione erano 77.800.000; questa è una cifra di base, non l'ammontare offerto.

ABVX: un accionista presentó un Formulario 144 para vender hasta 1.200.000 ADS, con un valor de mercado agregado de 111.300.000 dólares. La venta propuesta figura aproximadamente para el 28/10/2025 a través de Leerink Partners en NASDAQ.

Los valores se adquirieron en la OPV el 20/10/2023, con 1.200.000 ADS compradas al emisor y pagadas en efectivo el 24/10/2023. Las acciones en circulación eran 77.800.000; esta es una cifra base, no la cantidad que se ofrece.

ABVX: 주주가 Form 144를 제출하여 최대 1,200,000 ADS를 매도하고, 총 시가가 1억1130만 달러인 내용. 제안된 매도는 NASDAQ의 Leerink Partners를 통해 약 2025년 10월 28일에 시작될 예정입니다.

이 증권은 2023년 10월 20일 IPO에서 취득되었으며, 발행사로부터 1,200,000 ADS를 현금으로 2023년 10월 24일에 매입했습니다. 발행 주식 수는 77,800,000주였으며, 이는 기초 수치로써 제공되는 수량이 아닙니다.

ABVX : un actionnaire a déposé un Form 144 pour vendre jusqu'à 1 200 000 ADS, pour une valeur de marché cumulée de 111 300 000 dollars. La vente proposée est inscrite pour environ le 28/10/2025 via Leerink Partners sur le NASDAQ.

Les valeurs mobilières ont été acquises lors de l'introduction en bourse le 20/10/2023, avec 1 200 000 ADS achetées auprès de l'émetteur et payées en espèces le 24/10/2023. Les actions en circulation étaient de 77 800 000 ; il s'agit d'un chiffre de base, non le montant offert.

ABVX: Ein Aktionär hat ein Formular 144 eingereicht, um bis zu 1.200.000 ADS zu verkaufen, mit einem aggregierten Marktwert von 111.300.000 USD. Der vorgeschlagene Verkauf ist voraussichtlich ab dem ca. 28.10.2025 über Leerink Partners an der NASDAQ gelistet.

Die Wertpapiere wurden im IPO am 20.10.2023 erworben, wobei 1.200.000 ADS vom Emittenten gekauft und am 24.10.2023 in bar bezahlt wurden. Die ausstehenden Aktien betrugen 77.800.000; dies ist eine Basiszahl, nicht der angebotene Betrag.

ABVX: قدّم مساهم استمارة 144 لبيع حتى 1,200,000 ADS، بقيمة سوقية إجمالية قدرها 111,300,000 دولار. البيع المقترح مُدرج حوالي 28/10/2025 عبر Leerink Partners في NASDAQ.

تم الحصول على الأوراق المالية في اكتتاب عام أولي في 20/10/2023، مع شراء 1,200,000 ADS من المصدر ودفعها نقداً في 24/10/2023. كانت الأسهم المتداولة 77,800,000؛ هذه قيمة أساسية، وليست المبلغ المعروض.

ABVX:股东提交了 Form 144 以出售最多 1,200,000 ADS,总市值为 111,300,000 美元。拟议出售大约在 2025/10/28,通过 Leerink Partners 在 NASDAQ 上市。

证券在 2023/10/20 的首次公开募股中取得,向发行人购买了 1,200,000 ADS,并于 2023/10/24 以现金支付。在外流通股为 77,800,000 股;这是一个基线数字,并不是要出售的金额。

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did ABVX disclose in this Form 144?

A holder filed notice to sell up to 1,200,000 ADS on or about 10/28/2025.

What is the aggregate market value of the proposed ABVX sale?

The filing lists an aggregate market value of $111,300,000 for the 1,200,000 ADS.

Which broker and exchange are involved for ABVX?

The broker is Leerink Partners, and the shares are to be sold on NASDAQ.

When and how were the ABVX shares acquired?

They were purchased in the IPO on 10/20/2023 and paid in cash on 10/24/2023.

How many ABVX shares are outstanding?

The filing lists 77,800,000 shares outstanding.

What class of ABVX securities is included in the Form 144?

The filing covers ADS (American Depositary Shares).
Abivax S.A.

NASDAQ:ABVX

ABVX Rankings

ABVX Latest News

ABVX Latest SEC Filings

ABVX Stock Data

7.38B
73.57M
43.25%
2.15%
Biotechnology
Healthcare
Link
France
Paris